Hereditary Transthyretin Amyloidosis clinical trials

Explore recruiting hereditary transthyretin amyloidosis clinical trials.

Recruiting hereditary transthyretin amyloidosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hereditary Transthyretin Amyloidosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

Netherlands, Belgium, Cyprus, Spain, Portugal, Bulgaria +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 1 Two-Part (Open-label, Single Ascending Dose (Part 1) and Open-label, Single Dose Expansion (Part 2)) Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN).

France, Sweden

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

TRITON-PN: A Phase 3, Global, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy (hATTR-PN)

France, Italy, Greece, Spain, Sweden, Ireland +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Long-Term Follow-Up of Subjects Treated With NTLA-2001

Sweden, France

Phase II and Phase III (Integrated) EU CTIS Study details

Hereditary Transthyretin Amyloidosis trials by city

Hereditary Transthyretin Amyloidosis in Toronto Hereditary Transthyretin Amyloidosis in Vancouver Hereditary Transthyretin Amyloidosis in Montreal Hereditary Transthyretin Amyloidosis in Calgary Hereditary Transthyretin Amyloidosis in Edmonton Hereditary Transthyretin Amyloidosis in Ottawa Hereditary Transthyretin Amyloidosis in Winnipeg Hereditary Transthyretin Amyloidosis in Quebec City Hereditary Transthyretin Amyloidosis in Hamilton Hereditary Transthyretin Amyloidosis in Kitchener Hereditary Transthyretin Amyloidosis in London Hereditary Transthyretin Amyloidosis in Halifax Hereditary Transthyretin Amyloidosis in New York Hereditary Transthyretin Amyloidosis in Los Angeles Hereditary Transthyretin Amyloidosis in Chicago Hereditary Transthyretin Amyloidosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease